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A B S T R A C T   
In-depth characterization of heart-brain communication in critically ill patients with severe acute respiratory 
failure is attracting significant interest in the COronaVIrus Disease 19 (COVID-19) pandemic era during intensive 
care unit (ICU) stay and after ICU or hospital discharge. Emerging research has provided new insights into 
pathogenic role of the deregulation of the heart-brain axis (HBA), a bidirectional flow of information, in leading 
to severe multiorgan disease syndrome (MODS) in patients with confirmed infection with severe acute respi-
ratory syndrome coronavirus 2 (SARS-CoV-2). Noteworthy, HBA dysfunction may worsen the outcome of the 
COVID-19 patients. In this review, we discuss the critical role HBA plays in both promoting and limiting MODS in 
COVID-19. We also highlight the role of HBA as new target for novel therapeutic strategies in COVID-19 in order 
to open new translational frontiers of care. This is a translational perspective from the Italian Society of Car-
diovascular Researches.  
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1. Introduction: cardiovascular and brain disease susceptibility 
during COVID-19 pandemic 
Current concepts on the physiological and pathophysiological 
interdependence between the cardiovascular (CV) system and the brain 
under stress will be helpful in understanding adaptive response in 
COronaVIrus Disease 19 (COVID-19) patients, in discovering new 
pharmacological targets and in designing unexpected therapeutic stra-
tegies. Indeed, simultaneous injury of the heart and brain is emerging as 
a key risk factor for severe multiorgan disease in patients with confirmed 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneu-
monia [1–4]. Therefore, in-depth characterization of heart-brain 
communication in critically ill patients with severe acute respiratory 
failure following SARS-CoV-2 dissemination is attracting significant in-
terest in the COVID-19 pandemic era during intensive care unit (ICU) 
stay or after ICU or hospital discharge (3). 
The heart-brain axis (HBA) is characterized by bidirectional flow of 
information that may modulate susceptibility to injury both locally and 
systemically to other organs including the lungs [5]. The network of 
intramedullary neurons generating the sympathetic and para-
sympathetic outflow to the CV system is finely regulated by cortical 
neural control systems (i.e., medial prefrontal cortex, insular cortex, 
anterior cingulate cortex), the amygdala, the hypothalamus, and the 
hippocampus. These structures perceive and process an array of 
somato-visceral information, mainly CV afferent inputs, thereby initi-
ating an integrated pattern of endocrine, autonomic, and behavioral 
responses to emotionally relevant or stressful stimuli [6,7]. 
It is well known that psychosocial factors, such as social support, job 
loss, loneliness, social disruption, bereavement, social status, social 
distancing and lockdown, can contribute significantly to the pathogen-
esis of different non-communicable diseases, including acute myocardial 
infarction (AMI) and heart failure [8,9], stroke, cognitive impairment 
[10,11], major depressive disorder[12–14], chronic obstructive pul-
monary disease [15], asthma [16], obesity [17], chronic kidney disease 
[18] and cancer [19]. In the context of the COVID-19 pandemic, frail 
subjects are afraid of leaving home, being infected and going to the 
hospital when they perceive symptoms or comorbidities worsen 
[20–22]. These stressful environmental conditions mainly contribute to 
the onset of both CV and neurological complications in infected in-
dividuals at greatest risk of developing severe forms of COVID-19 and 
among the patients who show the first symptoms of COVID-19. Several 
reports, indeed, have shown that CV [23] and neurological morbidities 
[24–27] seriously worsen the outcome of COVID-19 patients, although 
the earlier clinical features remain fever, fatigue, decreased sense of 
smell and taste, and happy hypoxemia (extremely low blood oxygena-
tion without sensation of dyspnea) [28]. 
Herein we conduct an in-depth appraisal of the literature in order to 
depict how SARS-CoV-2 could interfere with the HBA, thereby impairing 
overall HBA homeostasis and simultaneously worsening acute respira-
tory failure and leading to major multiorgan complications, such as 
arrhythmias, AMI, stress-induced cardiomyopathy, stroke and neuro-
inflammatory disorders (Fig. 1). We further analyze first data on sex- 
related HBA alterations [29]. Finally, we describe how the modulation 
of signaling mediators of heart-brain crosstalk, including cytokines, 
neurotrophins and extracellular vesicles (EVs), could inspire different 
approaches in order to improve clinical outcome of COVID-19 patients. 
2. Neurotropism of SARS-CoV-2 short-circuits the neural 
cardiovascular control 
The nucleus of the solitary tract (NTS), located in the dorsal medulla 
oblongata, represents the first synaptic relay of the visceral afferent fi-
bers carrying sensory information from multiple structures, including 
arterial and cardiac baroreceptors, chemoreceptors, and lung stretch 
receptors. The different afferent information entering the NTS is 
conveyed both to brainstem and supramedullary sites (i.e., medial 
prefrontal cortex and insular cortex), which may in turn signal back to 
NTS neurons. This event produces the most appropriate autonomous 
response to adjust CV response to stimuli (i.e. tachycardia and vaso-
constriction/vasodilation in the alerting response) [30]. While acute 
responses are adaptive, they can turn in excessive sympathetic outflow 
and maladaptive chronic CV diseases (CVDs) in response to prolonged 
impairment of NTS. 
Hitherto unexpected SARS-CoV-2 neurotropism emerged [31], and 
the underlying mechanism has been object of intense investigation. 
From the very beginning of the pandemics, a variety of neurological 
symptoms, including loss of smell (hyposmia) and taste (hypogeusia), 
headache, nausea, vomiting, fatigue, have been reported in subjects 
affected by COVID-19 [24,32,33]. Additional neurological complica-
tions include stroke, impaired consciousness, seizures, and encepha-
lopathy [24,25]. Furthermore, the SARS-CoV-2 mRNA has been detected 
in the brain of 22 patients died by COVID-19 in Germany [34] and in the 
cerebral spinal fluid of a patient affected by encephalitis/meningitis 
even though its presence was not confirmed in the nasopharyngeal swab 
[35]. In agreement with these observations, angiotensin-converting 
enzyme 2 (ACE2), the main receptor that facilitates the entry of 
SARS-CoV-2 into host cells, is expressed in neurons from different brain 
regions [3,36,37]. The neurotropism even characterizes SARS-CoV [38, 
39], which has been identified in the cytosol of hypothalamic and 
cortical neurons [40,41], and Middle East Respiratory Syndrome Coro-
navirus (MERS-CoV) [42], which may infect thalamus and brainstem. 
Based on this similarity, SARS-CoV-2 could enter the central nervous 
system (SNS) through peripheral nerve terminals [1,4,31,36,43] or via 
the hematogenous/lymphatic route. The latter pathway is supported by 
the notion that brain microvascular endothelial cells express ACE2 [43, 
44] and, therefore, are susceptible for SARS-CoV-2 entry. In agreement 
with this hypothesis, viral structural and nonstructural genes have been 
detected in the endothelial layer of the frontal lobe of COVID-19 patients 
[45], as well as the viral Spike protein has been detected in over 95% of 
human microvascular brain endothelial cells by another independent 
study [46]. This evidence led some authors to suggest that SARS-CoV-2 
could infect brainstem neurons by crossing the blood-brain barrier (BBB) 
[31,43,47]. Alternately, SARS-CoV-2 could hijack macrophages, which 
also express ACE2 [48], to cross the BBB and to access the brain [47,49], 
as demonstrated for human immunodeficiency virus (HIV) [50], or it 
could infect the choroid plexus [47,51], thereby disrupting the 
blood-cerebrospinal fluid barrier. 
An additional route for SARS-CoV-2 to gain access to the brainstem is 
represented by olfactory nerve terminals [1,31]. Epithelial cells of the 
olfactory mucosa largely express ACE2 [52], whereas the olfactory 
nerve has long been known to provide a shortcut for several viruses, 
including influenza and West Nile virus, to enter CNS [53]. In accord 
with these observations, hyposmia is a common symptom among 
COVID-19 patients [31,36]. It has, therefore, been proposed that 
SARS-CoV-2 infects the olfactory neuroepithelium, whose neurons 
project dendrites into the nasal cavity, and then exploits the axonal 
retrograde transport machinery to reach the olfactory bulb via the 
cribriform plate. Once entered the CNS, SARS-CoV-2 could then use this 
mode of trans-synaptic transfer to propagate to other brain regions 
connected to the olfactory bulb, including amygdala, hypothalamus, 
limbic and pre-frontal cortex, piriform cortex, and brainstem [31,36, 
54], which contains the main centers responsible for the neural control 
of the CV function. This hypothesis, which was supported by an early 
report on SARS-CoV neurotropism [38], was confirmed by a recent 
investigation, showing that SARS-CoV-2 primarily infects the olfactory 
mucosa and then impinges on the transport along the olfactory tract of 
the central nervous system to reach the olfactory bulb and medulla 
oblongata [55]. Herein, severe microthromboembolic events were also 
detected and associated to local endothelial cell damage [55] due to 
axonal spreading of virus. These local ischemic infarctions are predicted 
to exacerbate the damage imposed by viral infection to the brainstem. 
Moreover, SARS-CoV-2-induced neuronal cell death pauperizes ACE2 in 
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Fig. 1. The scheme recapitulates the sequence of SARS-CoV-2 infectious disease evolution from high-risk subjects exposed to psychosocial stress towards patients 
with severe COVID-19 (A); (B) main features of heart-brain axis dysfunction in humans with interstitial pneumonia induced by SARS-CoV-2 following its vascular and 
transneuronal spreading. BDNF, brain-derived neurotrophic factor; HBA, heart-brain axis; IL, interleukin; MODS, multiorgan disease syndrome; ROS, radical oxy-
gen species. 
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the CV loci of NTS leading to chronic activation of the sympathetic 
system (with concomitant reduced vagal activity), which triggers 
different pathogenic mechanisms leading to CVDs (i.e., altered barore-
flex, endothelial dysfunction, atherosclerotic plaques, hypertension, left 
ventricular hypertrophy and arrhythmia) [56–59], beyond clinical evi-
dence of brainstem lesions [60]. Noteworthy, Cantuti-Castelvetri et al. 
provided further evidence regarding the SARS-CoV-2 neurotropism 
[61]. Based on the presence of a cleavage site for the protease furin in 
the spike protein of SARS-CoV-2, the authors showed that the virus uses 
neuropilin-1 (NRP1), a receptor that binds furin-cleaved substrates, for 
its entry and infectivity [61]. Unlike ACE2, NRP1 is highly expressed in 
the respiratory and olfactory epithelium [62]; therefore, this receptor 
could significantly potentiate SARS-CoV-2 infectivity by facilitating the 
interaction of the virus with ACE2. 
Hence, SARS-CoV-2 may spread through either the hematogenous 
route [63] or the retrograde transport along cranial nerves [64]. Since 
ACE2 receptors are highly expressed within the lower medulla [65], this 
is a beta-coronaviruses-susceptible area [38]. A proof of this peculiar 
neuro-morbidity is that epileptic attacks attributed to autonomic 
dysfunction have emerged in COVID-19 patients [66]. Moreover, as 
noticed above, the size of brainstem lesions may be enhanced by com-
bination of systemic inflammation, ischemic thrombotic/embolic le-
sions or ependymal capillary vasculitis within the brain ventricles [55, 
67]. Notably, we cannot exclude the confinement of SARS-CoV-2 in 
cranial nerve ganglia during remission and re-invasion of the CNS, heart 
and lungs via the axonal retrograde transport, in accord with other 
neurotropic viruses [68]. 
2.1. Autonomic imbalance may lead to stress-induced CV diseases 
Although coronaviruses can infect the autonomic center in the 
brainstem, potentially contributing to cardiovascular and respiratory 
failure, the direct effect of SARS-CoV2 on the autonomic nervous system 
is not well known yet. Actually, autonomic imbalance induced by 
physical and/or emotional stress is often associated with CVDs. The 
most remarkable example of emotional stress-induced cardiomyopathy 
is the Takotsubo syndrome (TTS) [69]. An excessive sympathetic 
response could significantly impact endothelial function, blood pres-
sure, cardiac phenotype (left ventricular hypertrophy and arrhythmia) 
and the renin-angiotensin-aldosterone system (RAAS) [69,70], thereby 
leading to hypertension, increased afterload and eventually congestive 
heart failure. It is conceivable that the abovementioned sequence of 
detrimental events may be triggered by the psychosocial stress imposed 
by COVID-19 pandemic [71,72] and possibly worsened by CNS infection 
and injury. 
Autonomic imbalance could seriously alter HBA in SARS-CoV-2- 
positive asymptomatic and paucisymptomatic patients, and in COVID- 
19 survivors, leading to multiple organ dysfunction syndromes 
(MODS) up to death. Post-traumatic stress disorder (PTSD), a common 
consequence of serious medical conditions [73] and major disasters, 
including the current COVID-19 pandemic [74], could lead to ischemic 
heart disease [75]. Indeed, PTSD is a significant risk factor in COVID-19 
survivors for CVDs, neurological diseases, including thromboembolic 
stroke [76–78], and airflow limitations [79]. The influence of PTSD on 
the HBA is well supported by the onset of acute coronary syndromes and 
major adverse cardiac events (MACEs), likely contributing to worsening 
outcomes even in cerebrovascular events in COVID-19 patients [80,81]. 
Moreover, PTSD was found to be an independent predictor of 
ischemic-appearing ECG changes on exercise treadmill tests in patients 
without known coronary artery disease (CAD), although PTSD patients 
are frequently exposed to traditional major CV risk factors (i.e., cigarette 
smoking, arterial hypertension, obesity) [82]. 
PTSD is indeed characterized by dysregulation of the hypothalamic- 
pituitary-adrenal axis, with increased cortisol release and sympathetic 
nervous system activation, similarly to patients with critical illnesses 
[83]. Elevated catecholamine levels enhance myocardial oxygen 
consumption, through an increase in heart rate, afterload and myocar-
dial contractility, and negatively affect vascular endothelial function, 
plaque stability and platelet function. Furthermore, PTSD-induced 
autonomic imbalance increases plasma glucose levels and RAAS activ-
ity with consequent insulin resistance and hypertension [84]. Besides 
acute renal outcomes (Na+ and water reabsorption), brain RAAS over-
activation might contribute to the development of hypertension and 
heart failure by jeopardizing neuroinflammation due to high ACE levels 
in the circumventricular organs (i.e., subfornical organ and area post-
rema) [85,86] and lower, albeit significant, expression in the hypo-
thalamus [87] and brainstem [88]. Since RAAS has a longer-term impact 
on inflammation, fibrosis and chronic oxidative stress [89], ACE in-
hibitors (ACEIs) and angiotensin II receptor blockers (ARBs) counteract 
arterial hypertension and heart remodeling in PTDS patients. Despite 
above mentioned drugs may induce ACE2 expression [90–92], 
SARS-CoV-2 may down-regulate ACE2 activity, favoring ACE/angio-
tensin II arm of the RAAS (76). Therefore, the scientific community does 
not encourage ACEIs withdrawal in hypertensive COVID-19 patients 
[23,92]. Moreover, we cannot ignore that emotional/physical stress 
associated with infection of cortical neurons may increase preload 
through water reabsorption by stimulating the 
hypothalamic-hypophyseal axis for antidiuretic hormone (ADH) release 
[93]. These detrimental effects of PTSD might be enhanced in patients 
with known CAD and hypertension, portending higher risk of MACEs 
during exposure to “cytokine storm”. 
Indeed, PTSD has been associated to a systemic inflammation which 
can per se contribute to atherosclerotic disease [94], which may be 
further exacerbated by the inflammatory burst reported in COVID-19 
[23], thereby leading to a vicious circle impairing HBA and providing 
a life-threatening pro-arrhythmic trigger. Nearly 50% arrhythmias in 
COVID-19 patients are due to direct myocardial damages caused by viral 
infection, hypoxia-induced apoptosis, and systemic inflammatory pro-
cess [95]. Noteworthy, proarrhythmic potential of systemic inflamma-
tion may result also from indirect neuronal mechanisms controlling 
heart rate. Inflammatory cytokines increase cardiac sympathetic 
outflow via central and peripheral pathways, namely the inflammatory 
reflex involving the hypothalamus and the left stellate ganglia activation 
[96]. It serves as a feedback system to putatively dampen elevated 
cytokine production and immune-inflammatory activation mediated by 
β2-adrenoceptors in circulating lympho-monocytes. Nevertheless, sym-
pathetic overactivation could favor ventricular arrhythmias even 
through activation of non-neuronal populations, such as astrocytes of 
the hypothalamus paraventricular nucleus [97]. It has been suggested 
correcting this sympathetic tone imbalance through vagus nerve stim-
ulation [98], which also has an anti-inflammatory effect. Indeed, a 
“cholinergic anti-inflammatory pathway” has been described as able to 
modulate, by a neural-immune link, the systemic response of the or-
ganism in the presence of pathogens producing faster beneficial effects 
with respect to the classical anti-inflammatory mechanisms (83). In the 
context of COVID-19-induced stress, characterized by a typical “fight or 
flight” sympathetic activation, the vagus stimulation may represent an 
additional protective strategy also for the cardiovascular system. Thus, 
by exploiting the brain’s ability to modulate systemic inflammatory 
responses to endotoxin, it would be possible to activate a rapid endog-
enous mechanism capable of suppressing the lethal effects of biological 
toxins during the “cytokine storm” induced by COVID syndrome. 
Alternatively, since α7 nicotinic acetylcholine receptors (α7-nAChRs) 
are potentially involved in modulating pro-inflammatory cytokine 
secretion and suppressing the “cytokine storm”, nicotinic cholinergic 
agonists should be examined as potential therapeutic options in the 
COVID syndrome [99,100]. 
3. SARS-CoV-2 and the bidirectional neuronal-to-vascular 
communication 
Due to the importance of vasculo-neuronal communication (VNC), 
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here we consider how COVID-19 may affect this important cross-talk 
between neuronal and vascular components of the CNS. Indeed, 
neuronal activity (NA) may directly tune the diameter of microvessels 
within the neurovascular unit (NVU) [101], a network of neurons, as-
trocytes, endothelial cells (ECs) and pericytes responsible for the local 
control of cerebral blood flow (CBF). Therefore, higher NA raises CBF 
towards activated brain regions [101,102]. Local changes in CBF may, in 
turn, signal back to adjacent neurons, modulating NA and synaptic 
plasticity according to VNC [103,104]. Mounting evidence showed that 
neuronal control of blood vessels initiates at capillaries level, which are 
better positioned to detect NA as they are closer than arterioles to firing 
neurons (8–23 µm vs. 70–160 µm) [101]. Capillaries, thus, could dilate 
even before “feeding arterioles” because of relaxation of pericytes 
running along the endothelial tube [101,105]. 
Somato-sensory stimulation may activate endothelial N-methyl-D- 
aspartate receptors (NMDARs) stimulating Ca2+-dependent nitric oxide 
(NO) release and triggering neurovascular coupling (NVC) [101,106]. 
NA-induced local K+ accumulation could activate endothelial 
inward-rectifier K+ channels and elicit a propagating hyperpolarization 
that causes upstream arteriolar relaxation via myoendothelial gap 
junctions [107]. Endothelial-mediated detection of NA could then be 
sustained by metabotropic glutamate receptors [108,109]. The 
following increase in CBF far exceeds the metabolic needs of the tissue, 
probably to subtly shape NA and synaptic activity [104] Indeed, an in-
crease in CBF may indirectly inhibit pyramidal NA through the 
TRPV4-dependent activation of perisynaptic astrocytes [103] which 
stimulate local interneurons [103] and regulate K+ homeostasis [110]. 
Furthermore, hemodynamic signals could potentiate shear 
stress-induced NO release from capillary ECs [101], which support 
long-term potentiation in several brain regions [111,112]. 
SARS-CoV-2 infected ECs in multiple vascular districts [113], 
including brain capillaries [45], thereby inducing endothelial dysfunc-
tion associated with apoptosis [55,113,114]. We cannot exclude that 
SARS-CoV-2 affects NVC by impairing EC ability to sense NA and release 
NO, an effect that could be exacerbated after COVID-19-induced peri-
cyte loss, which could arise either indirectly (because of stress-induced 
glucocorticoid signaling) [115] or directly (because of ACE2-mediated 
SARS-CoV-2 entry in pericytes) [116]. The emerging role of capillary 
signaling in NVC is a potential explanation for the high incidence of 
stroke [23] and the severe neurological complications in COVID-19 
patients [117]. Of note, also brain lymphatics are subjected to 
COVID-19-induced systemic endotheliitis [113] and could favor 
SARS-COV-2 entry into the brain [118]. Whether brain lymphatic, as 
major mediators of neuroinflammation and immune cell trafficking 
[119] are implicated in VNC derangement during SARS-COV-2 infec-
tion, remains to be determined. Thus, SARS-CoV-2 infection could 
worsen the HBA both systemically (by increasing the susceptibility to 
psychosocial factors) and locally (by interfering with the bidirectional 
neuronal-to-vascular communication). The altered VNC might increase 
the occurrence of headache, confusion, delirium, and poor outcomes, 
including mortality for stroke in COVID-19 patients. 
4. Heart-brain axis in COVID-19: role of sex 
COVID-19 similarly affects both sexes, but mortality in men is about 
two-fold than that of young women. Conversely, mortality is higher in 
both sexes in older subjects with pre-existing CV comorbidities [120, 
121]. Among COVID-19 patients, fewer women than men presented 
with cardiac injury, but those women with cardiac injury had higher 
levels of systemic inflammatory markers, suggesting a male inflamma-
tory phenotype [122]. Therefore, here we briefly consider sex-related 
HBA alterations and other sex/gender related issues, which may be 
also useful to develop personalized treatments. 
Women are more susceptible to psychosocial stress-induced injury 
than men are [123,124]. Besides social factors, this different suscepti-
bility to multiorgan injury originates, in part, from processes initiated 
during fetal development. For instance, men respond to stress with an 
increase in vascular resistance, while women with an increase in heart 
rate. The different molecular pathways between sexes involve numerous 
mediators, such as growth factors, neurotransmitters and RAAS. These 
factors influence differently the neuronal and vascular development of 
hypothalamic-pituitary-adrenal-axis regions (i.e., the paraventricular 
nucleus) controlling blood pressure [123]. Stress affects RAAS in the 
brain and heart leading to an imbalance in the ACE/ACE2 ratio and 
autonomic outflow. Sex differences in RAAS blood pressure regulation 
and in the pathophysiology of hypertension have been shown in both 
clinical and animal models [125]. As mentioned above, beta- 
coronaviruses target ACE2 and MODS is characterized by an unbal-
anced ACE/ACE2 ratio [91]. Since ACE2 is an anti- 
inflammatory/estrogen-regulated enzyme whose gene is on the 
X-chromosome, gender-related differences in ACE/ACE2 ratio and 
byproducts exist [126]. Moreover, transmembrane protease serine 2 
(TMPRSS2), an enzyme that primes spike S1 protein, is a testosterone 
regulated gene and may have a lower expression in women than in men 
[127]. Interestingly, aging alters activities of these enzymes besides 
hormones. Women have a longer life expectancy than men and this may 
explain why more women are infected than men over the age of 80 [23]. 
This is part of female-male health-survival paradox. 
A cardiac disease with strong correlation between stress and HBA is 
TTS, which has preference for postmenopausal women. Estrogen 
deprivation plays a facilitator role in TTS, likely involving endothelial 
dysfunction [128]. Increased cortisol and catecholamine release, and 
RAAS dysregulation, may lead to higher cardiac workload and many 
signs of acute phase of TTS. The causal relationship between TTS and 
RAAS is anecdotally demonstrated by the efficacy of ACEIs and ARBs in 
reducing the likelihood of recurrent episodes of apical, midventricular, 
or basal left ventricular ballooning [129,130]. Indeed, a Pubmed search 
for “Takotsubo and COVID-19” (Date accessed: 15/02/2021) provided 
89 results, one of which is about an inverted (basal) TTS in a 50-year-old 
man [131]. More recently, a minireview on TTS and COVID-19 has been 
published in which a few more cases are described [132]. TTS in 
COVID-19 has probably been underestimated so far, yet the investiga-
tion on its underlying mechanisms might shed light on the 
gender-related different HBA alterations induced by COVID-19. 
5. Potential therapeutic strategies: from drugs to functional 
foods 
HBA offers hitherto unexpected targets to develop innovative ap-
proaches of multiorgan protection and care in COVID-19 patients. 
5.1. Drug-based treatments 
Currently, there are no regulatory agency-approved medications for 
COVID-19. However, a multitude of drugs approved for other in-
dications are undergoing trials to repurpose their safety and efficacy 
(https://www.who.int/ictrp/en/). Most relevant compounds include: 
remdesivir (investigational antiviral) [133] and monoclonal antibodies 
disrupting the interaction of receptor binding domain of SARS-CoV-2 
Spike S1 protein with ACE2 receptor [134]. Hyperinflammation has 
provided the rationale for testing anti-inflammatory drugs to prevent the 
fatal “cytokine storm” in COVID-19. These include corticosteroids that 
were commonly used during previous pneumonia outbreaks, like SARS, 
and are currently used in COVID-19 patients, despite controversial ef-
ficacy [135]. Corticosteroids, like dexamethasone, may be useful in the 
short-term as they restrain the “cytokine storm”, while being detri-
mental in the long-term due to the inhibition of protective T cells and the 
block of B cell antibody production. Indeed, dexamethasone seems to 
reduce mortality only in critical COVID-19 patients [136], and meth-
ylprednisolone is a valid alternative to dexamethasone [137]. A case 
report showed that co-administration of methylprednisolone 
(200 mg/day, 4 days) and human immunoglobulin (20 g/day, 4 days) 
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may reverse myocardial injury and reduce cardiac troponin levels [138]. 
On the other hand, Ibuprofen, a commonly prescribed non-steroidal 
anti-inflammatory drug, reduced IL-6 levels in COVID-19 patients and 
several trials of anti-IL-6 therapies, like tocilizumab, are actively 
recruiting [139]. Finally, steroids and non-steroidal anti-inflammatory 
drugs even exert a dose-dependent inhibition of platelet aggregation by 
inhibiting intravascular microaggregation and pulmonary shunting as 
well. Since these drugs target pro-inflammatory processes and 
pro-thrombotic factors common to COVID-19, PTSD and HBA dysfunc-
tion, further studies are required to assess whether these drugs may 
attenuate the respiratory syndrome by exerting HBA protection. We 
cannot ignore that the potential therapies for COVID-19 discussed above 
have important toxicities that require caution, monitoring cardiac 
troponin levels (i.e., during chloroquine and hydroxychloroquine ther-
apy) [95] and the onset of delirium due to drug interactions (i.e.: during 
co-medication with psychotropic drugs) [140]. 
5.2. Extracellular vesicles 
Extracellular vesicles (EVs), nano-sized membrane-bound particles 
released by majority of the cells, are emerging as paracrine mediators 
between the brain and immune system in critically ill patients [141]. 
EVs can modulate target cells via their cargo, enriched by non-coding 
RNAs, such as microRNAs (miRNAs), proteins, lipids and other metab-
olites. Recently, plasma EVs have gained attention as new theranostic 
tool, given their protective and regenerative effects (such as in the case 
of mesenchymal progenitor stromal-EVs), as well as their possible 
diagnostic role even in older surgical patients [142]. Interestingly, 
endothelial and neural cells after brain injury can secrete EVs crossing 
the blood brain barrier, reaching peripheral organs and regulating sys-
temic inflammation [143]. Notably, EVs-delivered miRNA-126 supports 
cardiac function and is modulated following stroke. In fact, EVs isolated 
from ECs of conditional miR-126 knock-out mice display lower para-
crine protective effects on cultured cardiomyocytes exposed to 
hypertrophy-inducing stimuli [144]. Smallest EVs, also defined as exo-
somes, as isolated from several different sources of stem/progenitor 
cells, may exert neuro- and/or cardio-protective effects by quenching 
inflammation in several preclinical experimental models [145–151]. 
Thus, EVs may be involved in the HBA homeostasis under stress. 
ECs-derived EVs (EEVs) could be released upon SARS-CoV-2-induced 
endothelial injury, thereby contributing to the pro-inflammatory and 
pro-coagulant milieu, which underlies the fatal outcome of COVID-19 
[152,153]. Therefore, EEVs have been put forward as potential prog-
nostic peripheral blood markers in individuals potentially affected by 
COVID-19 [153]. Likewise, circulating EVs could be enriched with 
cardiac troponin and might represent another reliable prognostic 
marker of myocardial injury [154]. On the other hand, the therapeutic 
use of EVs isolated from Mesenchymal progenitor Stromal Cells (MSCs) 
in COVID-19 patients is actively debated. Allogenic MSCs display 
beneficial immunomodulatory activity in critically ill patients with 
acute respiratory distress syndrome (ARDS) [155], with their EVs 
reproducing most of the parental cell paracrine anti-inflammatory po-
tential [156]. Therefore, MSC-EVs are currently under consideration as 
putative supportive treatment to possibly tackle the systemic “cytokine 
storm” and hyper-activation of the immune cell system [135,157]. 
Despite some trials on the use of somatic or cardiac MSCs with or 
without additional treatment of MSC-EVs are ongoing in China, Iran and 
US [135,157], the International Society of Extracellular Vesicles (ISEV) 
and the International Society for Cell and Gene Therapy (ISCT) have 
very recently released a statement expressing specific concerns about 
EVs-based COVID-19 therapy [158]. Otherwise, ticagrelor, an estab-
lished anti-platelet drug, drives the release of antiapoptotic exosomes 
from human cardiac-derived progenitors [159], thereby suggesting an 
alternative approach to direct exosome transplantation in both vital 
organs beyond lowering the risk of thrombotic events. 
5.3. Functional foods 
Recent emphasis on the HBA protection has shifted to the epigenetic 
regulation of gene expression [160]. Enhancing the adaptive response of 
cardiac and brain cells without changing DNA sequence could improve 
outcome of critically ill patients [161]. Functional food components and 
their metabolites could prevent organ failure through the chemical 
modulation of chromatin structure and microRNAs release to pattern 
gene activity [162]. A recent study has highlighted the role of 
brain-derived neurotrophic factor (BDNF) as a crucial neurohormonal 
mediator within the HBA, as its levels are simultaneously decreased 
under oxidative stress [163]. Since failure of BDNF/TrkB signaling 
pathway is related to cardiac and hippocampal dysfunction, its decay 
may enhance the susceptibility to both cardiac and brain damage in 
SARS-CoV-2-positive patients [164]. Therefore, preventive use of func-
tional diet or artificial nutrition in the critical care setting with epige-
netically active dietary compounds may help to prevent/counteract 
organ failure or improve the outcome of critically ill patients. Pre-
liminary pre-clinical results have demonstrated that regular intake of 
barley beta-glucan or saffron, natural inhibitors of class I histone 
deacetylases (HDACs), or curcumin, a natural inhibitor of histone ace-
tyltransferases (HATs), may sustain the HBA through the upregulation of 
cardiac and hippocampal BDNF/TrkB pathway [160,165]. Moreover, 
sulforaphane, a hydrolysis product of glucoraphanin present in Brassica 
vegetables, enhances neuronal BDNF expression by inhibiting class I 
HDACs [166]. Moreover, diet supplementation with eicosapentaenoic 
acid (EPA) can prevent BDNF downregulation during neuro-
inflammation [167] since it reduces the expression of class I DNA 
methyltransferases (DNMTs) [160]. Resveratrol, a well-known natural 
polyphenol compound with anti-inflammatory properties [168] that 
enriches grapes, red wine, berries and extra virgin olive oil (EVOO), has 
been proposed to counteract SARS-CoV-2 [169] as it significantly abated 
Middle East Respiratory Syndrome Coronavirus (MERs-CoV) replication 
in vitro [170]. Since resveratrol targets DNMTs, HDACs and 
lysine-specific demethylase [171], it upregulates BDNF gene expression 
after 10 days oral intake [172]. So far, one randomized proof-of-concept 
clinical trial (NCT04400890) aimed to evaluate the safety and the 
effectiveness of resveratrol in two hundred COVID-19 patients. Both 
groups (Resveratrol and placebo) will also receive vitamin D3 (100,000 
IU) to augment the effects of resveratrol [173]. Interestingly, their 
combination has been also shown to act on HBA, by preventing cognitive 
decline [174] and ameliorating ischemia-reperfusion process after 
myocardial injury [175] in rodents. These results suggest that combi-
nation of different dietary compounds may lead to therapeutic food 
synergism, as aimed by ristoceutica, a new science announced in 2016 at 
Scuola Superiore Sant’Anna (Pisa, Italy) and directed to develop func-
tional meal based on combination of functional foods [161,176]. A 
specific smart diet is yet to be developed to prevent/attenuate the 
adverse effects of SARS-CoV-2 on the HBA. A better protection against 
viral infection is likely to be conferred by a varied dietary regimen 
[177]. Although the flavonoid quercetin is a reasonably potent inhibitor 
of the protease SARS-CoV-2 3CLpro (Ki ~ 7 μM) in vitro [178], foods 
rich of isoquercitrin (red onions, red raspberry, black grapes, broccoli, 
black tea), which is hydrolyzed to quercetin in the small intestine and 
rapidly absorbed, cannot replace the therapeutic treatment prescribed to 
severely ill COVID-19 patients. In accord with co-medications, associa-
tion of different foods rich of calcium and/or vitamin D could be suc-
cessfully suggested to reduce the side effects related to prolonged bed 
rest and steroid treatment (i.e. dairy products and salmon). Ristoceutical 
studies will be helpful to assess whether specific functional food com-
pounds, i.e. barley beta-glucan, isoquercitrin, curcumin and resveratrol, 
may act synergistically with commercially available drugs to hamper the 
viral infection and cytokine storm, and to counteract associated com-
plications related to their high dosage. Finally, Covid19 patients treated 
with steroids should avoid regular intake of foods that are high in salt 
and sugar in order to prevent the onset of metabolic disorders and 
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Fig. 2. Overview of proposed routes of heart-brain crosstalk leading to simultaneous heart and brain injury in COVID19 patients. ACE2, angiotensin-converting 
enzyme 2; BBB, blood brain barrier; BDNF, brain-derived neurotrophic factor; CV, cardiovascular; HPA, hypothalamic-pituitary-adrenal (HPA) axis; IL-6, inter-
leukin-6; LV, left ventricular; MDD, major depressive disorder; NVC, neurovascular coupling; NRP1, neuropilin 1; RAAS, renin–angiotensin–aldosterone system; ROS, 
radical oxygen species. 
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SARS-CoV-2-positive or COVID-19 patients developing heart and 
brain dysfunction is attracting growing interest. SARS-CoV-2 can inter-
fere with HBA either through direct neurotropism towards the neural CV 
control centers and by interfering with the local bidirectional neuronal- 
to-vascular communication or by increasing the susceptibility to psy-
chosocial factors resulting in emotional stress and/or anxiety, thereby 
potentially leading to cardiac hypertrophy, arrhythmia, AMI or TTS 
(Fig. 2). Perturbance of the delicate balance of neurohumoral cues 
regulating CV function may in turn damage brain by resulting in stroke. 
It is conceivable that the virus can spread to brain microvessels leading 
to pericyte loss and/or endothelial dysfunction, which may alter CBF 
through impairment of NVC regulation and recurrent microthrombotic 
events. The brain damage will in turn reinforce the vicious circle initi-
ated by SARS-CoV-2 infection triggering systemic inflammation that will 
further impact on cardiac function by enhancing oxidative stress, car-
diomyocyte remodeling, collagen deposition and rhythm alterations as 
well as macrophage infiltration [145]. Resident microglia activated 
upon injury produce cytokines, primarily IL-6 and IL-1β, which pass 
through the damaged blood-brain barrier. Furthermore, dying brain 
cells release damage-associated proteins that enter the systemic circu-
lation, activate Toll-like receptors (TLRs) and boost cytokine and che-
mokine production [69]. Notably, TLRs are also expressed in 
cardiomyocytes and have been implicated in the development of cardiac 
inflammation and heart failure [179]. Estrogens might protect the HBA 
both from the viral infection (because of gender-related differences in 
ACE/ACE2 ratio and in TMPRSS2 expression) and from the detrimental 
consequences of RAAS dysregulation (induced either by the emotional 
stress or by the direct infection of medulla oblongata). The 
above-mentioned complex scenario opens new avenues to identify un-
expected targets and develop innovative non –pharmacological 
personalized approaches, such as smart drugs, EVs and functional foods. 
Finally, rehabilitation is important for COVID-19 patients and survivors 
[180]. Indeed, the protection of HBA in COVID-19 patients who have 
mild symptoms could benefit from physical exercise which positively 
impacts on both CV function and mental health, as recently reviewed in 
[181]. Understanding the signaling pathways of HBA engaged by 
physical exercise to stimulate neurocardiac fitness is likely to speed up 
the identification of an effective pharmacological strategy to rescue HBA 
upon SARS-CoV-2 infection even in the presence of functional motor 
limitations. 
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